ARVO 2020: Two-Year Results of PANORAMA Favor Regular Schedule of Aflibercept in Treatment of Non-Proliferative Diabetic Retinopathy
Injections given every 16 weeks resulted in better outcomes than those given only as needed in year 2
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.